Baust John M, Van Buskirk Robert, Baust John G
Institute of Biomedical Technology, State University of New York, Binghamton, NY 13902, USA.
Cryobiology. 2002 Oct;45(2):97-108. doi: 10.1016/s0011-2240(02)00100-1.
The development of cryopreservation (CP) strategies has traditionally focused on the cellular chemo-osmometric characteristics attendant to the freeze-thaw process. This approach coupled with a limited understanding of cellular physiological and biochemical responses to the CP process often yields sub-optimal cell survival. Recently, we have reported on the benefits of the utilization of an intracellular-like preservation solution, HypoThermosol (HTS), as well as incorporating a molecular approach to improving CP outcome [In Vitro Cell. Dev. Biol. Anim. 36(4) (2000) 262]. We now report on the elucidation of a cryoprotective agent (CPA)-dependent survival limit (cap) associated with standard CP methodologies. We further demonstrate an elevation and shift in the CP cap through the utilization of HTS coupled with a reduction in CPA levels necessary to achieve "successful" cell preservation.
Human fibroblasts, keratinocytes, hepatic, and renal cells were cryopreserved in a standard fashion (approximately 1 degrees C min-1 cooling and storage in LN2) in culture media (serum-free) or HTS with varying levels of dimethyl sulfoxide (Me2SO). Samples were allowed to recover for 24-h prior to survival assessment. Survival was assessed using alamarBlue (metabolic activity indicator) and calcien-AM (membrane integrity stain) in comparison with non-frozen controls.
(1) A limit in cell survival was identified following CP in media-based CP solutions yielding a cell-type specific CPA-dependent survival limit, (2) peak cell survival resulted in the identification of "optimal" Me2SO concentrations for CP of each cell type, (3) incorporation of HTS as the carrier medium at typical Me2SO concentrations substantially elevated survival, and (4) utilization of HTS allowed for the successful preservation of all systems examined at significantly reduced Me2SO levels.
The data presented in this study illustrate that the utilization of HTS as the carrier medium during CP facilitated a significant improvement in efficacy at reduced Me2SO levels. Further, the utilization of HTS offers the potential for successful Me2SO-free CP. These findings may prove significant to the advancement in the development of cell-based clinical therapies by providing an improved biocompatible CP methodology.
传统上,冷冻保存(CP)策略的发展主要集中在冻融过程中伴随的细胞化学渗透压特征。这种方法加上对细胞对CP过程的生理和生化反应的有限理解,往往导致细胞存活率不理想。最近,我们报道了使用类似细胞内的保存溶液HypoThermosol(HTS)的好处,以及采用分子方法来改善CP结果[《体外细胞与发育生物学 - 动物》36(4) (2000) 262]。我们现在报告与标准CP方法相关的冷冻保护剂(CPA)依赖性存活极限(cap)的阐明。我们进一步证明,通过使用HTS,CP cap得到提高和偏移,同时实现“成功”细胞保存所需的CPA水平降低。
人成纤维细胞、角质形成细胞、肝细胞和肾细胞在培养基(无血清)或含有不同水平二甲基亚砜(Me2SO)的HTS中以标准方式(约1℃/分钟冷却并储存在液氮中)进行冷冻保存。在进行存活评估之前,让样品恢复24小时。与未冷冻的对照相比,使用alamarBlue(代谢活性指示剂)和钙黄绿素 - AM(膜完整性染色剂)评估存活率。
(1)在基于培养基的CP溶液中进行CP后,确定了细胞存活极限,产生了细胞类型特异性的CPA依赖性存活极限;(2)峰值细胞存活率导致确定了每种细胞类型CP的“最佳”Me2SO浓度;(3)在典型的Me2SO浓度下,将HTS用作载体介质可显著提高存活率;(4)使用HTS能够在显著降低的Me2SO水平下成功保存所有检测的系统。
本研究中呈现的数据表明,在CP过程中使用HTS作为载体介质有助于在降低Me2SO水平的情况下显著提高功效。此外,使用HTS为成功实现无Me2SO的CP提供了潜力。这些发现可能通过提供一种改进的生物相容性CP方法,对基于细胞的临床治疗发展的推进具有重要意义。